Access to this article is restricted until 12 months after publication by request of the publisher. Restriction lift date: 45635
STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact
dc.check.date | 45635 | en |
dc.check.info | Access to this article is restricted until 12 months after publication by request of the publisher | en |
dc.contributor.author | McGettigan, Siobhán | en |
dc.contributor.author | Curtin, Denis | en |
dc.contributor.author | O’Mahony, Denis | en |
dc.date.accessioned | 2024-02-06T16:48:42Z | |
dc.date.available | 2024-02-06T16:48:42Z | |
dc.date.issued | 45269 | en |
dc.description.abstract | Introduction: STOPP/START criteria for potentially inappropriate medications (PIMs, STOPP) and potential prescribing omissions (PPOs, START) have gained considerable interest and traction since they were first published in 2008. This review focuses on their uptake and impact in various clinical settings. Areas covered: STOPP/START criteria, now in their third iteration, are explicit criteria designed to facilitate detection of common and clinically important PIMs and PPOs during routine medication review in any clinical setting. We examine the influence of the criteria, particularly in clinical trials that focused on their impact on clinically relevant endpoints. Expert opinion: STOPP/START criteria are widely used in several countries within Europe and beyond for medication review and audit. As a discreet intervention, the criteria have been tested in several single-center and two large-scale multi-center clinical trials. The single-center trials indicate that STOPP/START criteria reduce polypharmacy, inappropriate prescribing, ADRs (adverse drug reactions), medication cost and falls. In contrast, the SENATOR and OPERAM multicentre trials did not demonstrate significant reduction in ADRs, all-cause mortality, drug-related hospital readmissions, nor any improvement in quality-of-life. Further clinical trials are required to examine whether STOPP/START criteria as an intervention can deliver significant clinical benefit in a reproducible manner in various clinical settings. | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Accepted Version | en |
dc.format.mimetype | application/pdf | en |
dc.identifier.citation | McGettigan, S., Curtin, D. and O’Mahony, D. (2023) 'STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact', Expert Review of Clinical Pharmacology, 16(12), pp. 1175-1185. doi: https://doi.org/10.1080/17512433.2023.2280219 | en |
dc.identifier.doi | 10.1080/17512433.2023.2280219 | en |
dc.identifier.eissn | 1751-2441 | en |
dc.identifier.endpage | 1185 | en |
dc.identifier.issn | 1751-2433 | en |
dc.identifier.issued | 12 | en |
dc.identifier.journaltitle | Expert Review of Clinical Pharmacology | en |
dc.identifier.startpage | 1175 | en |
dc.identifier.uri | https://hdl.handle.net/10468/15505 | |
dc.identifier.volume | 16 | en |
dc.language.iso | en | en |
dc.publisher | Taylor & Francis | en |
dc.rights | © 2023, Taylor & Francis Group, LLC. This is an Accepted Manuscript of an item published by Taylor & Francis in Expert Review of Clinical Pharmacology on 9 December 2023, available online: https://doi.org/10.1080/17512433.2023.2280219. It is deposited under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | en |
dc.subject | Polypharmacy | en |
dc.subject | STOPP/START criteria | en |
dc.subject | Older people | en |
dc.subject | Adverse drug events | en |
dc.subject | Medication review | en |
dc.subject | Multimorbidity | en |
dc.subject | Deprescribing | en |
dc.subject | Inappropriate prescribing | en |
dc.title | STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact | en |
dc.type | Article (peer-reviewed) | en |
dc.type | journal-article | en |
oaire.citation.issue | 12 | en |
oaire.citation.volume | 16 | en |
Files
Original bundle
1 - 2 of 2
Loading...
- Name:
- CORA STOPP START publication.pdf
- Size:
- 434.1 KB
- Format:
- Adobe Portable Document Format
- Description:
- Accepted Version
Loading...
- Name:
- CORA STOPP START publication.docx
- Size:
- 128.24 KB
- Format:
- Microsoft Word XML
- Description:
- Authors' original accepted version
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 2.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: